12 results about "Ribosomal protein E-L30" patented technology

The invention provides application of a paeoniflorin photoaffinity probe in screening key target protein of paeoniflorin, and relates to the technical field of chemical proteomics. The paeoniflorin photoaffinity probe has a structure as shown in a formula I, and the paeoniflorin key target proteins are 40S ribosomal protein S3 and statin 2. The paeoniflorin photoaffinity probe is applied to screening of the paeoniflorin key target proteins, so that two target proteins combined with paeoniflorin in liver cells are successfully identified; the two target proteins are respectively 40S ribosomal protein S3 (RPS3) and statin 2 (PHB2), and the two target proteins participate in the protection effect of paeoniflorin on the liver, and have the key effects of oxidation resistance, inflammation resistance, immunoregulation and the like in liver diseases.

The present disclosure provides methods for inducing cellular quiescence—defined as a reversible arrest of cell proliferation—by inhibiting ribosome biogenesis. The methods involve administering a quiescence-inducing agent, such as a small molecule inhibitor, peptide, antisense oligonucleotide, or targeted degrader, that interferes with rRNA transcription, processing, ribosomal protein synthesis, or ribosome assembly. The agent may be applied to cultured cells, tissues, organs, or organoids, across a range of cell types and species. In some embodiments, the methods reduce metabolic activity and enhance stress resistance in non-dividing or post-mitotic cells. By slowing proliferation and / or metabolism while preserving viability, these methods enable improved preservation of cells, tissues, and organs-enhancing transplantation logistics, biobanking, regenerative medicine workflows, and biological transport. Additional applications include studies of cell cycle regulation, tissue regeneration, stress biology, aging, and induction of organismal hypometabolism (e.g., torpor or hibernation). The disclosure includes examples demonstrating quiescence induction using chemical biology systems, pharmacological agents, and genetic approaches.

A self-inactivating lentiviral vector and method for treating or ameliorating Diamond-Blackfan anemia syndrome. The self-inactivating lentiviral vector includes nucleic acids encoding ribosomal protein S19 operably linked to an EF1α promoter or a MND promoter, wherein the nucleic acids encoding RPS19 are codon optimized for expression in human cells and are devoid of aberrant splice acceptor sites, thereby improving the safety and efficacy of the lentiviral vector.

The invention belongs to the technical field of gene engineering, and particularly relates to a ribosomal protein N'mutant and application thereof. The ribosomal protein N'mutant is subjected to Y190D mutation, and after the ribosomal protein N 'expressed by a production strain is subjected to Y190D mutation, the yield of LNT II is increased by 28.6%, the yield of LNnT is increased by 50%, the yield of LNT is increased by 92.3%, the yield of 3'-SL is increased by 13.8%, and the yield of 6 '-SL is increased by 20%. Therefore, after the 190th amino acid of the PriA is changed from tyrosine to aspartic acid, the production capacity of the PriA is improved, and when the PriA is applied to escherichia coli for producing the human milk oligosaccharide, the yield of the human milk oligosaccharide is remarkably improved finally.

The application discloses a method for engineering regulation of mRNA translation efficiency based on ribosome S1 protein acylation modification, and belongs to the field of genetic engineering and microbial protein expression. The method comprises the following steps: regulating the translation efficiency of mRNAs by modifying the acylation site of ribosome S1 protein; dynamically regulating the recruitment and translation efficiency of specific mRNAs by screening and identifying SBS sequences with different intensities under different acylation states of ribosome S1 protein; regulating the translation efficiency of specific mRNAs by the interaction force between ribosome S1 protein and SBS sequences; and dynamically regulating the translation efficiency of specific mRNAs by dynamically adjusting the acylation level of ribosome S1 protein. The application regulates the interaction between ribosome S1 protein acylation modification and SBS sequence optimization in the translation initiation process and influences the translation efficiency, which provides a new idea for designing a novel translation regulation element and improving the expression level of mRNAs.

Provided are methods for using chimeric proteins to produce RNA modifications that can be detected by sequencing methods, including methods detecting relative translation rates of various mRNAs. Also provided herein are compositions comprising chimeric proteins, wherein the chimeric proteins comprise a RNA editing protein and a ribosomal protein.

The invention provides a method for predicting myocarditis by using circular RNAcirc0071542 and ribosomal protein RPL13A. The method comprises the following steps: a) obtaining a biological sample of a subject; b) detecting the expression level of circACSL1 in the biological sample; c) comparing the expression level of the circACSL1 with a reference value from a healthy control; and d) when the expression level of the circACSL1 is higher than the reference value, judging that the subject has a myocarditis risk or is in a myocarditis state according to a difference value between the expression level of the circACSL1 and the reference value. The circACSL1 expression level is compared with the typical expression range of a dilated cardiomyopathy (DCM) subject to generate differential diagnosis data, and the expression difference of the marker between myocarditis and DCM can be utilized to effectively assist in clinically distinguishing the two diseases with different treatment strategies and prognosis but similar clinical manifestations.

The application belongs to the field of anticancer active natural ingredients, and particularly relates to an anticancer active glycoprotein, a preparation method and application thereof, and an anticancer drug for female cancer, wherein the anticancer active glycoprotein is a protein chemically bonded with selenium and polysaccharide, the protein includes a peroxidase domain protein, an RNA-dependent RNA polymerase, a nucleolar 278 pre-rRNA processing Urb / Npa2 C-terminal domain-containing protein, and a ribosomal protein S12; the polysaccharide chain is a sugar unit fragment with a structure of formula 1; the hydroxyl in the polysaccharide is connected to at least one amino acid in aspartic acid, valine, glutamic acid, arginine, lysine and serine in the protein through a hydrogen bond; and the selenium bond includes at least one of Se=O and Se-C-O. The application provides a novel structure of selenium glycoprotein ingredient, and further research shows that the ingredient can specifically inhibit female cancer cells and has a lower normal cell inhibition activity.

The application belongs to the technical field of biotechnology, and provides a Streptococcus suis type 2 (SS2) multi-epitope inhalation subunit vaccine and application thereof.Four CTL epitopes, seven HTL epitopes and six B cell epitopes are screened from the conserved epitopes of SS2 virulence factors SSU05-1022 and SpaA, and the four CTL epitopes, the seven HTL epitopes and the six B cell epitopes are fused by AAY / GPGPG / EAAAK linkers and introduced into L7 / L12 ribosomal protein as an adjuvant to construct an inhalation subunit vaccine 1022-SpaA V3.The vaccine is intranasally primed and boosted at 60 μg, can improve respiratory mucosa sIgA and serum IgG levels, activate related immune cells, and form a mucosal and systemic double immune mechanism.The survival rate of mice after SS2 multi-strain challenge is up to 100%, and the bacterial load can be reduced.The vaccine is safe and non-toxic, inhalation can save cost, and is suitable for industrial scale production.

The application provides a preparation method of 30S ribosomal protein S1 and use of the 30S ribosomal protein S1 as an antibacterial synergist, and belongs to the technical field of biological medicines. The 30S ribosomal protein S1 in the application is a bioactive protein produced by Acinetobacter bacteria, and has the effect of enhancing the antibacterial capacity of antibiotics. In the process of being combined with streptomycin sulfate, the 30S ribosomal protein S1 greatly enhances the inhibiting capacity of streptomycin sulfate on avian pathogenic E.coli without showing the effect of inhibiting bacteria itself, which lays a foundation for future practical application, and also plays a reference role for the development of new antibacterial synergists.

The application belongs to the technical field of genetic engineering, and particularly relates to a ribosomal protein N' mutant and application thereof. The ribosomal protein N' mutant is subjected to Y190D mutation. When the ribosomal protein N' expressed by a production strain is subjected to Y190D mutation, the production of LNT II is increased by 28.6%, the production of LNnT is increased by 50%, the production of LNT is increased by 92.3%, the production of 3'-SL is increased by 13.8%, and the production of 6'-SL is increased by 20%. It can be seen that after the 190th amino acid of PriA is changed from tyrosine to aspartic acid, the production capacity is improved. When the ribosomal protein N' mutant is applied to an Escherichia coli for producing human milk oligosaccharides, the production of human milk oligosaccharides is significantly improved.

In the present invention, when there is a peak of m / z 6766 + / -permissible error of ribosomal protein L30 derived from Mycobacterium abscessus subsp. Boleti as a result of mass spectrometry of a bacterium to be detected of Mycobacterium abscessus, it is determined that the bacterium to be detected is subsp. Boleti (steps 6, 7), and if there is a peak of m / z 6766 + / -permissible error of ribosomal protein L30 derived from Mycobacterium abscessus (steps 6, 7), it is determined that the bacterium to be detected is subsp. Boleti (steps 6, 7). The method comprises the following steps: determining that a bacterium to be detected is subspecies massiliensis if a peak of m / z 8767 + / -allowable error of ribosomal protein L29 derived from the subspecies massiliensis of Mycobacterium abscessus exists (steps 8 and 9), and determining that the bacterium to be detected is subspecies abscessus of Mycobacterium abscessus if both are not present (step 10). As a result, the subspecies of Mycobacterium abscessus (Mycobacterium abscessus) can be accurately, simply and conveniently identified.